Please assess the completion status of the following clinical trial:

Trial Title: Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. PADIS-PE Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a first episode of idiopathic pulmonary embolism who have been treated during 6 months (Plus 30 days or minus 15 days) using Vitamin K antagonist with a INR between 2 and 3.~Exclusion Criteria:~* Age \< 18~* warfarin hypersensibility~* unwilling or unable to give written informed consent~* distal or proximal deep vein thrombosis~* Pulmonary embolism which was provoked by a reversible major risk factor~* major thrombophilia (protein C, S or antithrombin deficiency, antiphospholipids antibodies, homozygous factor V Leiden)~* previous documented episode of proximal deep vein thrombosis or pulmonary embolism~* other indication for anticoagulant therapy (e.g.:atrial fibrillation, mechanic valve)~* patient on antithrombotic agent in whom antithrombotic agent should be started again after stopping anticoagulation~* pregnancy~* women without contraception~* planned major surgery in the next 18 months~* ongoing cancer or cured cancer in less than 2 years~* serious bleeding risk (e.g.: gastric ulcer)~* platelet count less than 100 Giga/l~* Life expectancy less than 18 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 18 months of active warfarin therapy
- 2 (Type: PLACEBO_COMPARATOR): 18 months of placebo of warfarin

Based on this trial design, predict the completion outcome and termination type (if applicable).